Understanding cover

Why cancer treatment costs vary so much between countries

The same treatment protocol can represent wildly different sums depending on where it is received.

In short

The cost of a course of cancer treatment varies enormously between countries. It depends on what drugs are priced at locally, whether the public system funds the newer targeted and immunotherapy agents, what equipment and expertise are available, and how long treatment lasts.

The same diagnosis, very different bills

Most people assume cancer is simply covered. It usually is, but “covered” is a statement about a benefit, and the cost of treatment can vary more between countries than almost anything else in medicine. The same diagnosis, treated to a comparable standard, can produce costs that are very different orders of magnitude depending on where you happen to be living.

We’re not going to quote a price for any treatment in any country. Published figures in this area are inconsistent, go out of date quickly, and describe a treatment plan that may not be yours. The number that matters to you is not an average cost: it is the limit written in your own policy.

What is worth understanding is why the variations exist.

What drives the variation

Drug pricing. Targeted therapies and the newer immunotherapy agents now account for a major share of what a treatment protocol costs, and their price is not uniform across countries. It depends on national pricing negotiations, reimbursement arrangements, patent status, and whether generics and biosimilars (close copies of biological medicines) are available in that market. The same drug can sit at quite different prices on either side of a border.

Whether the public system funds the newer treatments. This is the driver people miss. A country can have excellent oncology and still not fund a particular treatment through its public system. That’s either because it hasn’t been assessed as cost-effective there, or because it hasn’t been licensed locally at all. Where the public system pays, prices tend to be negotiated nationally and the invoice that reaches an insurer can be very different.

Technical capability. High-precision radiotherapy, robotic surgery, advanced imaging, molecular profiling of a tumour to decide which therapy to use: these are not available everywhere, and where they are, their use impacts the cost. Their absence has a cost too: it is often what turns a local case into a transfer abroad.

Duration. Cancer treatment is usually measured in months, sometimes in years, with prolonged follow-up and surveillance (regular checks for signs that the cancer has returned) afterwards. It is not a single event but a sustained expense, which is the decisive point when policy limits reset annually.

Why this matters more when you live abroad

At home, the question is mostly clinical. Abroad, two more questions come with it: whether the treatment you need is available where you live, and whether your policy will pay for it wherever you end up being treated.

Where advanced oncology is concentrated in a small number of centres, or isn’t available at all, a diagnosis becomes a logistics problem as well as a medical one. That’s the realistic position in Nigeria, where the most complex cases are treated abroad. The same applies in Senegal and Côte d’Ivoire, where advanced oncology regularly leads to Europe or Morocco, and in Cambodia and Indonesia, where serious cases routinely leave the country for Bangkok, Singapore or Ho Chi Minh City. In each of those, the oncology benefit and the evacuation benefit have to work together, or neither is much use.

Evacuation is not enough if the treatment does not follow

This is the gap that catches people out, and it’s worth stating plainly.

If you’re moving somewhere advanced oncology is hard to access, this is the question to ask explicitly, in these words: does your plan have a geographic restriction, or are the countries where you would likely receive treatment covered?

What to check in a policy

Two things, in order of how often they turn out to matter.

1. Is there a geographic restriction on the policy? Look for two things: whether the area of cover extends to the countries where a referral centre would realistically be, and whether the policy makes cover conditional on the drug being licensed in the country of treatment (a clause that can exclude an option that is available elsewhere).

2. What happens at renewal after a claim? A policy isn’t a one-year purchase. Ask, separately, whether premium increases after a large claim are applied to you individually or across a pool of policyholders. Rising renewal premiums are usually a market-wide phenomenon rather than a personal penalty, and our guide to why premiums rise explains the mechanisms, but the renewability clause is what stops you being left without cover at the point you most need it.

These questions sit alongside the other structural questions in how to choose an insurer, and they’re the reason it’s worth reading the oncology terms in the policy wording rather than the brochure.

A diagnosis before you buy is a pre-existing condition

A cancer diagnosed before your cover starts is a pre-existing condition and will be treated as one: generally speaking an active cancer diagnosis will lead to decline of your application. That is not a quirk of oncology: it is how underwriting works for everything, and it is set out in our guide to pre-existing conditions.

Two practical consequences follow.

The first is that you need international cover in place before anything appears, not after. There’s no version of this market in which a policy bought after a diagnosis pays for that diagnosis.

The second is less obvious and matters more to people who are already insured: switching insurer after a diagnosis is usually the wrong move. A new insurer considers you a new client and will normally treat the condition as pre-existing, even though you were continuously covered for it until the day you switched. Your continuous cover doesn’t automatically travel with you. If you have an active condition and are thinking about changing policy (because of price, an employer change, or a move), take advice before you cancel anything. Cancelling first and shopping around afterwards is the sequence that does real damage.

The number that concerns you

There’s no useful average cost of treating cancer abroad. Anyone quoting one is describing a treatment protocol that’s probably not yours, in a country that’s probably not where you’ll be treated. The variation between countries is real, and it’s the reason the benefit exists in the form it does.

The figure worth knowing is the one on your own schedule of benefits, the table that sets out what your policy pays: the oncology limit, how it’s applied, and where in the world it can be spent.

Common questions

Why does cancer treatment cost so much more in some countries than others?

Several drivers compound one another. Targeted therapies and newer immunotherapy treatments account for a large share of a treatment protocol's cost, and they aren't priced uniformly between countries. Pricing depends on national negotiations, reimbursement arrangements and whether generics or biosimilars are available. Whether the public system funds those newer agents can impact the bill again. So does the availability of high-precision radiotherapy, robotic surgery and advanced imaging. And treatment often runs for months or years, so duration compounds every other factor.

Will my policy pay for cancer treatment in another country?

It depends on the wording, and this is the gap that catches people. Check that the area of cover extends to the countries where a referral centre would realistically be.

What happens to my policy at renewal after a cancer claim?

This is why guaranteed renewability matters. A guaranteed renewable policy is one the insurer undertakes to renew regardless of the claims you've made or the conditions you've developed, without re-underwriting you individually (assessing your health again). Ask separately whether increases after a large claim are applied to you individually or across a pool of policyholders. Switching insurer after a diagnosis is usually the wrong move, because a new insurer will underwrite and will treat the condition as pre-existing.

Start your comparison

Six short questions. One shortlist.

  1. Step 1 of 6
  2. Step 2 of 6
  3. Step 3 of 6
  4. Step 4 of 6
  5. Step 5 of 6
  6. Step 6 of 6
Step 1 of 6

Who is this comparison for?